150 related articles for article (PubMed ID: 21519217)
1. Tuberculosis infections and tumor necrosis factor alpha antagonists.
Gan J; Manadan AM; Sequiera W; Block JA
Am J Ther; 2013 Jan; 20(1):73-8. PubMed ID: 21519217
[TBL] [Abstract][Full Text] [Related]
2. [Adverse effects of biologic agents in treatment of rheumatoid arthritis--prevention of tuberculosis].
Tomono K; Hashimoto S
Nihon Rinsho; 2005 Jan; 63 Suppl 1():573-8. PubMed ID: 15799420
[No Abstract] [Full Text] [Related]
3. Tuberculosis screening in prescribers of anti-tumor necrosis factor therapy in the European Union.
Smith MY; Attig B; McNamee L; Eagle T
Int J Tuberc Lung Dis; 2012 Sep; 16(9):1168-73. PubMed ID: 22794309
[TBL] [Abstract][Full Text] [Related]
4. Infections associated with tumor necrosis factor-alpha antagonists.
Rychly DJ; DiPiro JT
Pharmacotherapy; 2005 Sep; 25(9):1181-92. PubMed ID: 16164393
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
Carmona L; Gómez-Reino JJ; Rodríguez-Valverde V; Montero D; Pascual-Gómez E; Mola EM; Carreño L; Figueroa M;
Arthritis Rheum; 2005 Jun; 52(6):1766-72. PubMed ID: 15934089
[TBL] [Abstract][Full Text] [Related]
6. Tuberculosis and anti-TNF-alpha treatment.
Ormerod LP
Thorax; 2004 Nov; 59(11):921. PubMed ID: 15516463
[No Abstract] [Full Text] [Related]
7. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents.
Doherty SD; Van Voorhees A; Lebwohl MG; Korman NJ; Young MS; Hsu S; National Psoriasis Foundation
J Am Acad Dermatol; 2008 Aug; 59(2):209-17. PubMed ID: 18485527
[TBL] [Abstract][Full Text] [Related]
8. Prevention of tuberculosis in patients taking tumor necrosis factor-alpha blockers.
Bellofiore B; Matarese A; Balato N; Gaudiello F; Scarpa R; Atteno M; Bocchino M; Sanduzzi A
J Rheumatol Suppl; 2009 Aug; 83():76-7. PubMed ID: 19661550
[TBL] [Abstract][Full Text] [Related]
9. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection.
Gómez-Reino JJ; Carmona L; Angel Descalzo M;
Arthritis Rheum; 2007 Jun; 57(5):756-61. PubMed ID: 17530674
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor blockers and reactivation of latent tuberculosis.
Keane J
Clin Infect Dis; 2004 Aug; 39(3):300-2. PubMed ID: 15306994
[No Abstract] [Full Text] [Related]
11. Tumour necrosis factor-alpha and tuberculosis: guidance from the National TB Advisory Committee.
Kavanagh PM; Gilmartin JJ; O'Donnell J; O'Flanagan D
Ir Med J; 2008 Jan; 101(1):6-7. PubMed ID: 18369014
[No Abstract] [Full Text] [Related]
12. [Increased risk of infection with biological immunomodifying antirheumatic agents. Clear guidelines are necessary as shown by case reports].
Söderlin M; Blomkvist C; Dahl P; Forsberg P; Fohlman J
Lakartidningen; 2005 Dec 5-11; 102(49):3794-6, 3799-800. PubMed ID: 16408703
[TBL] [Abstract][Full Text] [Related]
13. Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India -- An audit report.
Malaviya AN; Kapoor S; Garg S; Rawat R; Shankar S; Nagpal S; Khanna D; Furst DE
J Rheumatol; 2009 Jul; 36(7):1414-20. PubMed ID: 19487263
[TBL] [Abstract][Full Text] [Related]
14. Serious infections associated with anticytokine therapies in the rheumatic diseases.
Giles JT; Bathon JM
J Intensive Care Med; 2004; 19(6):320-34. PubMed ID: 15523118
[TBL] [Abstract][Full Text] [Related]
15. Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment.
Dinarello CA
J Rheumatol Suppl; 2005 Mar; 74():40-7. PubMed ID: 15742464
[TBL] [Abstract][Full Text] [Related]
16. Miliary tuberculosis following negative latent tuberculosis infection screening prior to tumor necrosis factor-α antagonists: implications for management?
Teh BW; Street AC; McBryde ES; Denholm JT
J Rheumatol; 2012 Jun; 39(6):1297-8. PubMed ID: 22661422
[No Abstract] [Full Text] [Related]
17. Skin lesions and treatment with tumor necrosis factor alpha antagonists.
Hernández MV; Meineri M; Sanmartí R
Reumatol Clin; 2013; 9(1):53-61. PubMed ID: 22766431
[TBL] [Abstract][Full Text] [Related]
18. Recommendations to lower the risk of tuberculosis in patients treated with tumour necrosis factor alpha antagonists.
Gómez-Reino J; Carmona L
Acta Reumatol Port; 2006; 31(3):201-3. PubMed ID: 17094331
[No Abstract] [Full Text] [Related]
19. TNF-alpha antagonists: pulmonary legionellosis.
Prescrire Int; 2007 Feb; 16(87):20. PubMed ID: 17326282
[TBL] [Abstract][Full Text] [Related]
20. Disseminated tuberculosis secondary to adalimumab.
Pednekar M; Chandra AB; Chandra PA
Am J Ther; 2012 Jul; 19(4):e139-40. PubMed ID: 20838203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
